A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome

Trial Profile

A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs Filgrastim (Primary) ; Plerixafor (Primary)
  • Indications WHIM syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2018 Planned End Date changed from 31 Mar 2021 to 31 May 2021.
    • 06 Jun 2018 Planned primary completion date changed from 30 Sep 2020 to 30 Nov 2020.
    • 13 Jul 2017 Planned End Date changed from 30 Jun 2020 to 31 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top